Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 7/20 | 0.45 |
| ▸ | CDK2 | P24941 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197423 | 1.00 | CETP (0.45) | CETPCDK2GAARAB9ALNPEP | |
| SCHEMBL13197424 | 0.89 | CETP (0.41) | CETPCDK2GAARAB9ALNPEP | |
| SCHEMBL2837376 | 0.86 | CETP (0.61) | CETP | |
| SCHEMBL2840610 | 0.86 | CETP (0.61) | CETP | |
| SCHEMBL2831774 | 0.78 | CETP (0.63) | CETP | |
| SCHEMBL13197422 | 0.77 | ESR1 (0.45) | CETPESR1ESR2 | |
| SCHEMBL13059849 | 0.77 | CETP (0.43) | CETP | |
| SCHEMBL13197459 | 0.76 | CETP (0.76) | CETP | |
| SCHEMBL13059646 | 0.75 | ESR2 (0.53) | CETPRAB9AESR1ESR2 | |
| SCHEMBL2837378 | 0.75 | CETP (0.52) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | CETP 1/4885CDK2 3859/4885GAA 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.